Maravai LifeSciences Holdings Inc [MRVI] stock prices are up 1.18% to $8.61 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MRVI shares have gain 3.24% over the last week, with a monthly amount glided 13.14%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Maravai LifeSciences Announces March 2024 Investor Conference Schedule. In a post published today on Yahoo Finance, Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.
From an analyst’s perspective:
Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] stock has seen the most recent analyst activity on December 12, 2023, when BofA Securities upgraded its rating to a Buy and also revised its price target to $8 from $10. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on August 08, 2023. On May 23, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $14 on the stock. Goldman downgraded its rating to a Neutral. UBS downgraded its rating to a Neutral and reduced its price target to $16 on January 05, 2023. Deutsche Bank started tracking with a Buy rating for this stock on December 14, 2022, and assigned it a price target of $25. In a note dated December 07, 2022, RBC Capital Mkts initiated an Outperform rating and provided a target price of $22 on this stock.
The stock price of Maravai LifeSciences Holdings Inc [MRVI] has been fluctuating between $4.52 and $16.62 over the past year. Currently, Wall Street analysts expect the stock to reach $23.5 within the next 12 months. Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] shares were valued at $8.61 at the most recent close of the market. An investor can expect a potential return of 172.94% based on the average MRVI price forecast.
Analyzing the MRVI fundamentals
The Maravai LifeSciences Holdings Inc [NASDAQ:MRVI] reported sales of 288.94M for trailing twelve months, representing a drop of -63.78%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at 2.14%, and Net Profit Margin reading is -0.42%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.24 and Total Capital is -0.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.42 points at the first support level, and at 8.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.79, and for the 2nd resistance point, it is at 8.96.
Maravai LifeSciences Holdings Inc [MRVI] reported earnings per share of $0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.01/share, meaning a difference of $0.02 and a surprise factor of 200.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.01 per share as compared to estimates of $0.01 per share, a difference of -$0.02 representing a surprise of -200.00%.
Ratios To Look Out For
It’s worth pointing out that Maravai LifeSciences Holdings Inc [NASDAQ:MRVI]’s Current Ratio is 8.00. In addition, the Quick Ratio stands at 7.41 and the Cash Ratio stands at 6.57. Considering the valuation of this stock, the price to sales ratio is 3.94, the price to book ratio is 2.73.
